[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"doc-seo-461712-105":3,"detail-sidebar-cat-0-en-105":81,"doc-detail-461712-en":130},{"code":4,"msg":5,"data":6},0,"ok",{"site_id":7,"language":8,"slug":9,"title":10,"keywords":11,"description":12,"schema_data":13,"social_meta":74,"head_meta":76,"extra_data":78,"updated_unix":80},105,"en","real-world-experience-with-janus-kinase-inhibitors-in-extraintestinal-manifestations-and-inflammatory-bowel-disease-in-colombia-a-comparative-study-jakeim-ibd-study","Real-world experience with Janus kinase inhibitors in extraintestinal manifestations and inflammatory bowel disease in Colombia: A comparative study (JAKEIM-IBD Study)","","Extraintestinal manifestations (EIMs) substantially affect patients with inflammatory bowel disease (IBD), influencing quality of life and clinical complexity. This multicenter real-world study evaluates Colombian patients with moderate-to-severe IBD and EIMs treated with upadacitinib or tofacitinib, assessing prevalence, resolution, and progression of EIMs. Among 77 patients, most EIMs were articular; induction response and maintenance remission were reported, with no significant difference in remission rates between treatments. Adverse events included alopecia, acne, and herpes zoster.",{"@graph":14,"@context":73},[15,34,56],{"@type":16,"itemListElement":17},"BreadcrumbList",[18,23,27,31],{"item":19,"name":20,"@type":21,"position":22},"https://docshare.wps.com","Home","ListItem",1,{"item":24,"name":25,"@type":21,"position":26},"https://docshare.wps.com/document/","Document",2,{"item":28,"name":29,"@type":21,"position":30},"https://docshare.wps.com/document/healthcare/","Healthcare",3,{"item":32,"name":10,"@type":21,"position":33},"https://docshare.wps.com/document/real-world-experience-with-janus-kinase-inhibitors-in-extraintestinal-manifestations-and-inflammatory-bowel-disease-in-colombia-a-comparative-study-jakeim-ibd-study/461712/",4,{"url":32,"name":10,"@type":35,"image":36,"author":41,"headline":10,"publisher":44,"fileFormat":47,"inLanguage":8,"description":12,"dateModified":48,"datePublished":49,"encodingFormat":47,"isAccessibleForFree":50,"interactionStatistic":51},"DigitalDocument",{"url":37,"@type":38,"width":39,"height":40},"https://docshare.wps.com/thumbnails/real-world-experience-with-janus-kinase-inhibitors-in-extraintestinal-manifestations-and-inflammatory-bowel-disease-in-colombia-a-comparative-study-jakeim-ibd-study/461712.png","ImageObject",300,407,{"name":42,"@type":43},"dawugda","Person",{"url":19,"name":45,"@type":46},"DocShare","Organization","application/pdf","2026-10-31","2026-09-30",true,{"@type":52,"interactionType":53,"userInteractionCount":55},"InteractionCounter",{"@type":54},"ViewAction",10,{"@type":57,"mainEntity":58},"FAQPage",[59,65,69],{"name":60,"@type":61,"acceptedAnswer":62},"What was the main aim of the JAKEIM-IBD Study?","Question",{"text":63,"@type":64},"To describe real-world outcomes in Colombian patients with IBD and extraintestinal manifestations treated with upadacitinib or tofacitinib, including prevalence, resolution, and progression of EIMs.","Answer",{"name":66,"@type":61,"acceptedAnswer":67},"What types of extraintestinal manifestations were most common?",{"text":68,"@type":64},"Articular manifestations were most frequent (81.25%), followed by hepatobiliary (25%), cutaneous (18.75%), and ocular (6.25%).",{"name":70,"@type":61,"acceptedAnswer":71},"Were remission outcomes different between upadacitinib and tofacitinib?",{"text":72,"@type":64},"No significant difference in remission rates was observed between upadacitinib and tofacitinib (OR 1.36, 95% CI 0.43-4.33, P=0.28).","https://schema.org",{"og:url":32,"og:type":75,"og:title":10,"og:site_name":45,"og:description":12},"article",{"robots":77,"canonical":32},"index,follow",{"doc_id":79,"site_id":7},461712,1791187425,{"code":4,"msg":82,"data":83},"success",[84,88,92,96,101,106,110,115,120,123,126],{"id":22,"doc_module":4,"doc_module_name":25,"category_name":85,"show_sort_weight":86,"slug":87},"Story & Novel",90,"story-novel",{"id":26,"doc_module":4,"doc_module_name":25,"category_name":89,"show_sort_weight":90,"slug":91},"Literature",80,"literature",{"id":33,"doc_module":4,"doc_module_name":25,"category_name":93,"show_sort_weight":94,"slug":95},"Exam",70,"exam",{"id":97,"doc_module":4,"doc_module_name":25,"category_name":98,"show_sort_weight":99,"slug":100},5,"Comic",60,"comic",{"id":102,"doc_module":4,"doc_module_name":25,"category_name":103,"show_sort_weight":104,"slug":105},6,"Technology",50,"technology",{"id":107,"doc_module":4,"doc_module_name":25,"category_name":29,"show_sort_weight":108,"slug":109},7,40,"healthcare",{"id":111,"doc_module":4,"doc_module_name":25,"category_name":112,"show_sort_weight":113,"slug":114},8,"Research & Report",30,"research-report",{"id":116,"doc_module":4,"doc_module_name":25,"category_name":117,"show_sort_weight":118,"slug":119},9,"Religion & Spirituality",20,"religion-spirituality",{"id":118,"doc_module":4,"doc_module_name":25,"category_name":121,"show_sort_weight":118,"slug":122},"World Cup","world-cup",{"id":55,"doc_module":4,"doc_module_name":25,"category_name":124,"show_sort_weight":55,"slug":125},"Lifestyle","lifestyle",{"id":127,"doc_module":4,"doc_module_name":25,"category_name":128,"show_sort_weight":97,"slug":129},19,"General","general",{"code":4,"msg":82,"data":131},{"doc_id":79,"user_id":132,"nickname":42,"user_avatar":133,"doc_module":4,"category_id":107,"category_name":29,"doc_title":10,"doc_description":12,"doc_content":134,"file_id":135,"file_url":136,"file_type":137,"file_size":138,"view_count":55,"is_deleted":4,"is_public":22,"is_downloadable":22,"audit_status":22,"page_count":139,"language":140,"language_code":8,"site_id":7,"html_lang":8,"table_of_contents":141,"faqs":142,"seo_title":143,"seo_description":12,"update_tm":144,"read_time":145,"preview_page_count":4},3985747870947,"https://ap-avatar.wpscdn.com/davatar_3d24733baf745e90a7e4bdd5f77d97b2","ORIGINAL ARTICLE  \nINFLAMMATORY DISEASE  \nHIGHLIGHTS  \n• Upadacitinib and tofacitinib effectively controlled EIMs and reduced corticosteroid dependence.  \n• Safety profile was favorable, with mainly mild infections and herpes zoster.  \n• JAK inhibitors represent effective and safe options for IBD with extraintestinal involvement.  \n• Both agents achieved sustained remission of extraintestinal manifestations during maintenance therapy.  \nReceived: 30 March 2025  \nAccepted: 29 August 2025  \nDeclared conflict of interest of all authors: none  \nDisclosure of funding: none Declaration of use of artificial intelligence: none  \nData availability statement: Not applicable – The study did not use research data  \nCorresponding Author: Juan Sebastian Frías-Ordoñez. E-mail:  \n[jsfriaso@unal.edu.co](jsfriaso@unal.edu.co).  \nAssociate editor: José Miguel L. Parente  \n[doi.org/10.1590/S0004-2803.24612025-045](doi.org/10.1590/S0004-2803.24612025-045)  \nReal-world experience with Janus kinase inhibitors in extraintestinal manifestations and inflammatory bowel disease in Colombia: A comparative study (JAKEIM-IBD Study)  \nViviana PARRA-IZQUIERDO1,2 , Oscar ARDILA3 , Juan Ricardo MÁRQUEZ4 , Javier RIVEROS5 , Álvaro Andrés GÓMEZ-VENEGAS6 ,  \nCarlos Andrés MEDRANO-ALMANZA7 , Manuel BALLESTEROS8 , Jonathan BARRETO-PÉREZ9 and Juan Sebastian FRIAS-ORDOÑEZ10  \n1 Hospital Internacional de Colombia, Gastroenterology and Rheumatology, Bucaramanga, Colombia.  \n2 El Bosque University, Cellular and Molecular Immunology Group-InMuBo, Bogota, Colombia.  \n3 CES Clinic, Gastroenterology, Medellín, Colombia. 4 Instituto ICO, Coloproctology, Medellin, Colombia.  \n5 Clínica de La Mujer, Gastroenterology, Bogotá, Colombia. 6 Private practice, Gastroenterology, Medellin, Colombia. 7 Gastroadvanced IPS, Gastroenterology, Medellin, Colombia. 8 Intergastro, Gastroenterology, Medellin, Colombia. 9 Medicarte, Gastroenterology, Bogota, Colombia. 10 Hospital Internacional de Colombia, Gastroenterology, Bucaramanga, Colombia.  \nABSTRACT–Background–Extraintestinal manifestations (EIMs) significantly impact patients with inflammatory bowel disease (IBD). Janus kinase inhibitors (JAKi) are emerging as a potential treatment. This study describes real-world outcomes in Colombian patients with IBD and EIMs treated with upadacitinibor tofacitinib. Methods–Multicenter study including moderate-to-severe IBD patients with EIMs. We analyzed the prevalence, resolution, and progression of EIMs with JAKi therapy. Results – Among 77 patients (51 UC-tofacitinib, 16 UC-upadacitinib, 10 CD-upadacitinib), 28.6%(n=22) had EIMs, primarily articular (81.25%), followed by hepatobiliary (25%), cutaneous (18.75%), and ocular (6 .25%) . Most tofacitinib-UC patients (90%) had prior anti-TNF therapy. During induction, 66.6% had a clinical response, and 33.3% achieved EIM remission. In maintenance, 83.3% achieved remission. Among upadacitinibUC patients, 66.6% had prior anti-TNF, 33.3% anti-integrin, and 33.3% were biologic-naïve. Corticosteroid use was reduced in 66.7% . Induction response was 66.7%, with 33.3% achieving remission. At six months, remission was 50% . No significant difference in remission rates was observed between upadacitinib and tofacitinib (OR 1.36, 95%CI 0.43-4.33, P=0 .28) . In CD-upadacitinib, all patients had prior anti-TNF therapy, with 66.6% achieving remission during induction. Adverse events included alopecia, acne, and herpes zoster. Conclusion–JAKi therapy is a safe and effective alternative for IBD patients with EIMs. While upadacitinib may offer superior intestinal benefits, both treatments demonstrated efficacy in managing EIMs.  \nKeywords – Extraintestinal manifestations; janus kinase inhibitors; inflammatory bowel diseases; therapy; therapeutics; disease management; drug-related side effects and adverse reactions.  \nArq Gastroenterol • 2025. v. 62:e25045  113   \nReal-world experience with Janus kinase inhibitors in extraintestinal manifestations and inflammatory bowel","cbCaidi4mZKtIHs0","https://ap.wps.com/l/cbCaidi4mZKtIHs0","pdf",312381,13,"English","# Highlights\n## Upadacitinib and tofacitinib outcomes\n## Safety profile and remission\n## Study context in Colombia\n# Abstract\n## Background and objectives\n## Methods\n## Results\n## Adverse events\n## Conclusion\n# Keywords\n# Introduction\n## Challenge of EIMs in IBD\n## Current therapies and variability in response\n## Emerging treatments and guideline gaps","[{\"question\":\"What was the main aim of the JAKEIM-IBD Study?\",\"answer\":\"To describe real-world outcomes in Colombian patients with IBD and extraintestinal manifestations treated with upadacitinib or tofacitinib, including prevalence, resolution, and progression of EIMs.\"},{\"question\":\"What types of extraintestinal manifestations were most common?\",\"answer\":\"Articular manifestations were most frequent (81.25%), followed by hepatobiliary (25%), cutaneous (18.75%), and ocular (6.25%).\"},{\"question\":\"Were remission outcomes different between upadacitinib and tofacitinib?\",\"answer\":\"No significant difference in remission rates was observed between upadacitinib and tofacitinib (OR 1.36, 95% CI 0.43-4.33, P=0.28).\"}]","Real-world experience with Janus kinase inhibitors in extraintestinal manifestations and inflammatory bowel disease in Colombia: A comparative study (JAKEIM-IBD Study) | PDF",1790762215,33]